Drug containing liver targeting specific ligand and thyroid hormone receptor agonist
AssigneeKylonova (Xiamen) Biopharma Co., Ltd.
InventorKunyuan Cui
Life of this patent
Estimating the term…
Loading patent…
AssigneeKylonova (Xiamen) Biopharma Co., Ltd.
InventorKunyuan Cui
Estimating the term…
Provided is a drug containing a liver targeting specific ligand and a thyroid hormone receptor agonist in its structure, which is a new drug structure formed by linking the liver targeting specific ligand with the thyroid hormone receptor agonist through a branched chain, a linker and a linking chain. Thyroid hormone receptors (TRs) are divided into two subtypes, TR-α and TR-β, wherein, TR-β is mainly expressed in liver, and TR-α is mainly expressed in heart, nervous system, etc. In certain embodiments, it is envisaged that the provided drug has the action of liver targeting, can specifically bring the thyroid hormone receptor agonist into liver, without entering heart and other issues, and may thereby avoid side effects caused by the action of the thyroid hormone receptor agonist on other issues, and maintain its therapeutic efficacy in the treatment of lipid metabolism disorders and related complications.
A compound containing a liver targeting specific ligand and a thyroid hormone receptor agonist in the structure, wherein the liver targeting specific ligand X is connected to the thyroid hormone receptor agonist T sequentially through a branched chain L containing a structure for stabilizing steric hindrance, a linker B and a linking chain D, and the compound is represented by Formula (I) of
Dependencies are inferred from the claim text.